<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The purpose of our study was to correlate the incidence of adequate implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) interventions in <z:hpo ids='HP_0001639'>hypertrophic cardiomyopathy</z:hpo> (HCM) patients with risk markers (RMs) for <z:hpo ids='HP_0001645'>sudden cardiac death</z:hpo> (SCD) plus <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> as detected by late <z:chebi fb="0" ids="33375">gadolinium</z:chebi>-enhanced cardiac magnetic resonance (LGE-CMR) imaging </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In <z:hpo ids='HP_0000001'>all</z:hpo>, 87 patients with HCM underwent LGE-CMR imaging prior to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation, performed for secondary (n = 2; 2%) or primary SCD prophylaxis (n = 85; 98%) </plain></SENT>
<SENT sid="2" pm="."><plain><z:mp ids='MP_0003045'>Fibrosis</z:mp> was graded with a 17-segment left ventricular model (0 = absent, 1 = point-shaped, 2 = limited to 1 left ventricular segment, 3 = involving ≥ 2 segments) </plain></SENT>
<SENT sid="3" pm="."><plain>During follow-up, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> memories were read out by a physician blinded to the individual patient data </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The number of RMs per patient was 1.9 ± 0.8 </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0001685'>Myocardial fibrosis</z:hpo> was present in 78 patients (90%); 26 (30%) had a <z:mp ids='MP_0003045'>fibrosis</z:mp> score of 3 </plain></SENT>
<SENT sid="6" pm="."><plain>During follow-up (3.5 ± 2.6 [range, 0.2-11.4 years]), 15 patients had 50 appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> interventions </plain></SENT>
<SENT sid="7" pm="."><plain>Episodes of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> were found in 28 patients </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0003045'>Fibrosis</z:mp> severity correlated with occurrence of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (Cramér's V, or φc = 0.4, P &lt; 0.001) and <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (φc = 0.6, P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>On multivariate regression analysis, an independent association between <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> (ß = 0.6, P &lt; 0.01) and sustained <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> was found </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In HCM patients treated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> implantation because of a high SCD risk by traditional RM assessment, a high rate of arrhythmic events was observed during long-term follow-up </plain></SENT>
<SENT sid="11" pm="."><plain>In a cohort of patients with clinical markers for high risk of SCD, severity of <z:hpo ids='HP_0001685'>myocardial fibrosis</z:hpo> as detected by an easy LGE-CMR scoring system was associated with future arrhythmic events and appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies </plain></SENT>
</text></document>